New York, N.Y., March 06, 2024 - PRISM MarketView - IceCure Medical Ltd. (Nasdaq: ICCM) has announced new data from a preliminary, independent breast cancer study showing median tumor reduction of 100% at six and 12 months following cryoablation in women deemed inoperable for breast cancer. IceCure’s ProSense® System is a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal.
“We are so pleased that women in this study, who were deemed inoperable, benefitted from cryoablation. We are working hard to get ProSense® approved, available and affordable for as many women as possible in a number of countries around the world.”
IceCure CEO, Eyal Shamir
Highlights
IceCure’s clinical trial was a single-site study. Ultrasound-guided cryoablation using ProSense® was performed on 39 women aged 60-92, who had biopsy-proven malignant lesions, and were deemed inoperable due to advanced age and comorbidities, or who refused surgery.
Patients were monitored at 1, 3, 6 and 12 months post-procedure, at which time the tumor size reduction rate was evaluated by ultrasound.
At 12 months post-procedure, the effectiveness of the procedure was further evaluated by core needle biopsy on the post-procedural scar and contrast enhanced mammography (“CEM”) to determine the presence or absence of residual tumoral cells and effectiveness of cryoablation.
ProSense® is approved in Italy for numerous indications, including breast cancer. The ProSense® System offers a minimally invasive procedure that takes up to 40 minutes to complete.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and China.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
PRISM MarketView does not provide investment advice.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)